Wound healing is not impaired by the epidermal growth factor receptor-tyrosine kinase inhibitor gefitinib [4]

Annals of Oncology

Volumn 14, Issue 8, 2003, Pages 1330-1331

  Govindan, R ^a,b   Behnken, D ^a,b   Read, W ^a,b   McLeod, H ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b USA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; PROTEIN TYROSINE KINASE INHIBITOR;

ABDOMINAL PAIN; ABSCESS; ABSCESS DRAINAGE; AGED; BONE METASTASIS; CANCER PATIENT; CASE REPORT; ENZYME INHIBITION; FEMALE; GENE OVEREXPRESSION; HUMAN; LAPAROTOMY; LETTER; LUNG NON SMALL CELL CANCER; MALE; METASTASIS; PRIORITY JOURNAL; SKIN INCISION; SKIN INJURY; SOLID TUMOR; SPLENECTOMY; WOUND HEALING; WOUND HEALING IMPAIRMENT;

EID: 0042510372     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdg352     Document Type: Letter

References (5)

1. de Bono JS, Rowinsky EK. The ErbB receptor family: a therapeutic target for cancer. Trends Mol Med 2002; 8 (4 Suppl): S19-S26.
2. Greenhalgh DG. The role of growth factors in wound healing. J Trauma 1996; 41: 159-167.
3. Tokumaru S, Higashiyama S, Endo T et al. Ectodomain shedding of epidermal growth factor receptor ligands is required for keratinocyte migration in cutaneous wound healing. J Cell Biol 2000; 151: 209-220.
4. Yamaguchi Y, Yoshikawa K. Cutaneous wound healing: an update. J Dermatol 2001; 28: 521-534.
5. Nakamura Y, Sotozono C, Kinoshita S. The epidermal growth factor receptor (EGFR): role in corneal wound healing and homeostasis. Exp Eye Res 2001; 72: 511-517.